Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
Ultragenyx reported Q1 2026 revenue of $136 million, slightly down from the prior year, but reaffirmed full-year 2026 revenue guidance of $730 million to $760 million and maintained its path to profitability in 2027. The pipeline delivered significant catalysts, including positive top-line Phase 3 data for DTX301 showing a statistically significant 18% reduction in plasma ammonia, while GTX-102 Phase 3 data are expected in the second half of 2026.
Key figures
- Revenue
- 136000000
- Guidance
- 2026 total revenue $730 million to $760 million; combined R&D and SG&A expenses flat to slightly down versus 2025
- Net loss
- $185 million
- Cash balance
- $534 million
- Ux111 pdufa date
- September 19, 2026
- Dtx401 pdufa date
- August 23, 2026
- Operating expenses
- $305 million
- Dtx301 ammonia reduction
- 18%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.